Skip to search formSkip to main contentSkip to account menu

PI3K-delta Inhibitor TGR-1202

Known as: TGR-1202 
An orally bioavailable, selective inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinases (PI3K) with… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Matthew S. Davids, MD1, Ian W. Flinn, MD, PhD2,3, Anthony R. Mato, MD4, Owen A. O'Connor, M.D., Ph.D.5, Danielle M. Brander, MD6… 
2016
2016
7512Background: TGR-1202 is a novel, once-daily PI3Kδ inhibitor with a differentiated safety profile from other PI3Kδ inhibitors… 
2016
2016
Introduction The oral BTK inhibitor ibrutinib is highly effective at inducing partial responses (PR) in relapsed or refractory (R… 
2015
2015
Background: TGR-1202 is a novel, next generation PI3Kδ inhibitor which exhibits a differentiated safety profile from other PI3K… 
2015
2015
Introduction: TGR-1202 is a next generation, once daily, oral PI3Kδ inhibitor that displays promising clinical activity in… 
2015
2015
Introduction: Ublituximab (UTX) is a novel anti-CD20 mAb that has been glycoengineered for enhanced ADCC. TGR-1202 is a novel… 
2014
2014
2513 Background: TGR-1202 is a novel, next generation PI3Kδ inhibitor. Preliminary data from an ongoing Ph I study of TGR-1202… 
2014
2014
Background: TGR-1202 is a novel oral, next generation PI3Kδ inhibitor which notably lacks the hepatotoxicity associated with… 
2013
2013
Background The constitutively activated PI3K/AKT/mTOR pathway plays a key role in the proliferation and survival of cancer cells…